| Literature DB >> 34959446 |
Adrian Dervan1,2,3, Antonio Franchi1,2, Francisco R Almeida-Gonzalez1,2,3, Jennifer K Dowling4,5, Ohemaa B Kwakyi4,6, Claire E McCoy4,5, Fergal J O'Brien1,2,3, Alan Hibbitts1,2,3.
Abstract
Injury to the peripheral or central nervous systems often results in extensive loss of motor and sensory function that can greatly diminish quality of life. In both cases, macrophage infiltration into the injury site plays an integral role in the host tissue inflammatory response. In particular, the temporally related transition of macrophage phenotype between the M1/M2 inflammatory/repair states is critical for successful tissue repair. In recent years, biomaterial implants have emerged as a novel approach to bridge lesion sites and provide a growth-inductive environment for regenerating axons. This has more recently seen these two areas of research increasingly intersecting in the creation of 'immune-modulatory' biomaterials. These synthetic or naturally derived materials are fabricated to drive macrophages towards a pro-repair phenotype. This review considers the macrophage-mediated inflammatory events that occur following nervous tissue injury and outlines the latest developments in biomaterial-based strategies to influence macrophage phenotype and enhance repair.Entities:
Keywords: biomaterials; central nervous system; immunology; inflammation; macrophage; peripheral nerve; regenerative medicine
Year: 2021 PMID: 34959446 PMCID: PMC8706646 DOI: 10.3390/pharmaceutics13122161
Source DB: PubMed Journal: Pharmaceutics ISSN: 1999-4923 Impact factor: 6.321
Figure 1Schematic diagram of macrophage polarization after nerve injury. Macrophages constantly undergo phenotypic polarization depending on the current environmental stimuli. M1 macrophages are activated by TLR ligands, LPS, TNFα, IFN-γ. Activation into M2 macrophages occurs when macrophages are exposed to IL-4, IL-13, TGF-β, immune complexes and A2AR agonist. (Adapted from [3,4], Wolters Kluwer, 2019 and Springer Berlin Heidelberg, 2015. Created with Biorender®).
Figure 2Temporal changes in macrophage phenotype during PNI and repair.
Figure 3Temporal changes in macrophage phenotype during CNS injury and repair. Timelines for cell infiltration, repair stages and M2 phenotype transition in the wound site were obtained from the following sources.
Figure 4Overview of the scar region of the sciatic nerve for weeks after injury following chronic M1 macrophage activation. The schematic depicts crucial elements of the scar including blood vessels, collagen fibrils and contributing cells in the scar formation process. HSP47—Heat shock protein 47, αSMA—alpha Smooth Muscle Actin (Adapted from [39], John Wiley & Sons, Inc., 2020).
Physical modifications for the polarization of macrophages during PNI.
| TECHNIQUE/PRODUCT | |||
|---|---|---|---|
| Physical Approach | In vitro/In vivo | Immune Response | Ref |
|
| |||
| Micropatterns | BMDMs C57Bl/6J mice | Elongated macrophages on micropatterns express M2 phenotype biomarkers | [ |
|
| |||
| Aligned nanofibers | * Sciatic nerve from SD rats | Higher expression of arg1, IL-10 and higher M2/M1 ratio compared to random nanofibers | [ |
|
| |||
| Micropatterns | PBMCs human macrophages | More M2 macrophages expressed in post patterns than line patterns and greater distance between posts induce a stronger anti-inflammatory effect | [ |
|
| |||
| Micropatterns and GO nanosheets | * Sciatic nerve in SD rats | Micropatterned and GO-modified conduit promotes M2 phenotype differentiation | [ |
|
| |||
| Pores and fibers size | Sciatic nerve SD rats | Macroporous nanofiber wrap increases IL-10 expression and decreases TNF-α expression and M1/M2 ratio on the injury site | [ |
Annotation: Bone marrow derived macrophages (BMDMs); poly(l-lactide-co-caprolactone) (P(LLA-CL)); peripheral blood mononuclear cells (PBMCs); Sprague Dawley® (SD); graphene oxide (GO); Arginase-1 (arg1); interleukin-10 (IL-10); Tumour necrosis factor alpha (TNF-α); * In vitro and in vivo.
Chemical modifications for the polarization of macrophages during PNI.
| TECHNIQUE/PRODUCT | |||
|---|---|---|---|
| Chemical Approach | In vitro/In vivo | Immune Response | Ref |
|
| |||
| Genipin crosslinking | THP-1 cells | Crosslinking of outer conduit reduced | [ |
|
| |||
| Graphene modification and electrical stimulation | * Sciatic nerve 4-week-old SD rats | Induced change in macrophages phenotype from M1 to M2 | [ |
|
| |||
| Graphene modification | Raw 264.7 macrophages | Macrophages seeded onto graphene crosslinked conduit show high expression of CD163 and CD206 markers | [ |
|
| |||
| Nanodiamond addition | Sciatic nerve in male SD rats | Nanodiamonds induce M2 polarization of macrophages | [ |
Annotation: Sprague Dawley® (SD); * In vitro and in vivo.
Therapeutic molecule incorporation to induce macrophage polarization during PNI.
| TECHNIQUE/PRODUCT | |||
|---|---|---|---|
| Biological Approach | In vivo | Immune Response | Ref |
|
| |||
| Sustained release of Collagen VI | Sciatic nerve in SD rats | Promotes polarization of macrophages towards M2 phenotype | [ |
|
| |||
| Local delivery of IL-4 or IFN-γ | * Sciatic nerve in adult Lewis male rats | IL-4 or IFN-γ polarizes macrophages towards M2 and M1 phenotypes, respectively | [ |
|
| |||
| Local delivery of IL-10 | Sciatic nerve in Wistar rats | IL-10-conjugated PCL scaffold induces M2 polarization | [ |
|
| |||
| Local delivery of Fractalkine | Sciatic nerve in Lewis rats | Fractalkine promotes the recruitment of anti-inflammatory macrophages | [ |
|
| |||
| Miconazole | * C57BL/6 mice | Suppresses M1 phenotype and induces M2 phenotype | [ |
| Thrombomodulin | In vivo: sciatic nerve in male SD rats and In vitro: THP-1 cells | Promotes nerve repair by M2 polarization | [ |
| Vitamin B | Femoral nerve in AO rats | promotes M2 polarization, reduces pro-inflammatory cytokines and increases anti-inflammatory cytokines | [ |
|
| |||
| EPI-NCSCs delivery | Sciatic nerve in adult female SD rats | Delivery decreases inflammatory fibroblasts and increases the M2/M1 macrophages ratio | [ |
|
| |||
| SKPSCs delivery | In vivo: Sciatic nerve in adult Lewis rats; In vitro: unprimed adult macrophages with SKPSC-conditioned medium | SKPSCs enhances expression of arg1 and an increases number of CD206+ macrophages. Nonetheless, these cells were associated with high levels of pro-inflammatory cytokines | [ |
|
| |||
| miR-21 antagomir or miR-21 deletion | In vivo: spared nerve injury in mice; In vitro: PECs with exosome-enriched media from sensory neurons | miR-21-5p expression was associated with pro-inflammatory phenotype. Inhibition of miR-21-5p promoted M2 phenotype | [ |
| EV-miR-23a | antagomir In vivo: spared nerve injury in mice; In vitro: coculture of DRG neurons with mouse macrophages | EV encapsulated miR-23a promoted M1 polarization. Inhibition of miR-23a reduced M1 macrophages numbers and increases M2 macrophages | [ |
Annotation: Sprague Dawley® (SD); interleukin-10 (IL-10); Albino Oxford (AO); epidermal neural crest stems cells (EPI-NCSCs); Arginase-1 (arg1); Peritoneal exudate cells (PECs); Extracellular vesicles (EVs); * In vitro and in vivo.
Organic and synthetic constructs used to induce macrophage polarization in central nerve injury. Where ↑ indicates an increase in specific cells population and ↓ indicates a decrease in specific cell population.
| Biomaterial | Model | Level | Delivery | Duration | Therapeutic | Effect | Ref |
|---|---|---|---|---|---|---|---|
| Peripheral Nerve (Decellularized hydrogel) | SCI | C3/C4 | Injection | 14 days | none | No change M1 CCR7+ cells | [ |
| Brain, cord and urinary bladder | SCI | T8 | Injection | 56 days | none | Spatial differences in CD86+ (M1) and CD206+ (M2) cells | [ |
| Urinary bladder | Rat | Middle cerebral artery occlusion Cortex | Injection | 14 days | none | No change CD86+ (M1) cells | [ |
| (Decellularized | Rat | T9-10 | Injection | 56 days | none | ↓ total ED1+ cells | [ |
| Collagen | SCI | T7-11 | Scaffold | 28 days | MSCs | ↓total CD68+ macrophages | [ |
| Gelatin | SCI | T10-11 | Scaffold | 56 days | MSCs | ↓total CD68+ macrophages | [ |
| HA combined with PCL spun fibers | SCI | T9 | Scaffold | 28 days | none | No change CD86+ (M1) cells | [ |
| Agarose/polyethylene glycol/carbomer | SCI | Aneurysm clip compression | Scaffold | 9 days | MSCs | ↑TNF-α (M1) and 10-fold ↑ arginase-1 | [ |
| Chitosan and water as fragmented physical hydrogel suspension | Rat | Bilateral | Injection | 56 days | none | ↓ CD86+ (M1) expression | [ |
Chemical methods that modify macrophage polarization in CNS injury. Where ↑ indicates an increase in specific cells population and ↓ indicates a decrease in specific cell population.
| Biomaterial | Model | Level | Delivery | Duration | Therapeutic | Effect | Ref |
|---|---|---|---|---|---|---|---|
| Oligo[poly(ethylene glycol) fumarate (OPF) plus Matrigel | SCI | T9-10 | Scaffold | 56 days | Schwann cells | No change CD86+ (M1) cells | [ |
| Poly(glycolic acid) | SCI | T10-11 | Scaffold | 56 days | NPCs | ↓CD68+ macrophages | [ |
| PLGA and Poly- | SCI | T10 | Scaffold | 84 days | none | ↓CD74 + (M1) cells | [ |
| GO | Rat | C6 | Scaffold | 10/30 days | none | Day 10: No change CD80+ (M1) and CD163+ (M2) cells | [ |
| PLGA | mice | T9-T10 | Scaffold | 30 days | none | No change F4/80+ arginase1- (M1) cells | [ |
| PLGA | mice | T9-T10 | Scaffold | 28 days | none | ↓ CD86, MHCII, iNOS (M1) expression | [ |
| PLGA | mice | C5 | Scaffold | 84 days | none | ↑F4/80+/Arginase-1+ (M2) cells | [ |
Nanoparticle formulation methods for modifying macrophage polarization in central nerve injury. Where ↑ indicates an increase in specific cells population and ↓ indicates a decrease in specific cell population.
| Biomaterial | Model | Level | Delivery | Duration | Therapeutic | Effect | Ref |
|---|---|---|---|---|---|---|---|
| Chitosan | SCI | C3-C4 | Spongostan® | 7 days | None | ↓ ED-1+ | [ |
| Minocycline loaded poly-caprolactone | Mice | T12 Unilateral stab/ injection | Cord | 15 days | None | ↓ CD68+ | [ |
| Flavopiridol loaded PLGA nanoparticles | SCI | T9-10 | Topical delivery | 42 days | None | ↓CD68+ macrophages | [ |
| Hirudin loaded Pluronic F-127 hydrogels | mice | T8 | Cord injection | 28 days | none | ↓CD68+ macrophages | [ |
| PLGA | mice | T9-10 | PLGA | 84 days | none | ↓ iNOS+, CD86+, and MCP-1+(M1) expression | [ |
| Minocycline hydrochloride complexed with polysaccharide dextran sulphate | SCI | C5 | Agarose | 42 days | none | ↓CD68+ macrophages | [ |
| Chicago sky blue loaded liposomes | SCI | T9 | Intravenous injection | 4 days | none | ↑ CCL2, IL-1β, and iNOS (M1) expression | [ |
Summary of the different types of stem cell used to treat CNS injury and their effect on macrophage number and phenotype in the lesion site. Where ↑ indicates an increase in specific cells population and ↓ indicates a decrease in specific cell population.
| Biomaterial | Model | Level | Delivery | Duration | Therapeutic | Effect | Ref |
|---|---|---|---|---|---|---|---|
| None | SCI | T9-10 | Injection | 35 days | MSCs | ↓ iNOS+, CD16+/32+ (M1) cells | [ |
| Gelatin sponge scaffolds sheathed with PLGA film | SCI | T10-11 | Scaffold | 56 days | MSCs | ↓ CD68+ macrophages | [ |
| PLGA | SCI | T9-10 | Scaffold | 10 days | MSCs | ↓ CD68+ macrophages | [ |
| Methacrylamide chitosan hydrogel | Rats | T8-9 | Scaffold | 56 days | NPSCs | ↓ ED-1+ macrophages | [ |